Simon Kerry, Curve Therapeutics CEO (Image: Advent Life Sciences)

UK biotech draws Pfiz­er back­ing in £40.5M Se­ries A for pep­tide-in­spired drugs

Curve Ther­a­peu­tics has raised £40.5 mil­lion ($51.4 mil­lion) in a Se­ries A round to ad­vance its small cyclic pep­tide-based dis­cov­ery plat­form and drug can­di­dates, in­clud­ing plans for a Phase I can­cer tri­al in 2026.

The pro­ceeds will be used to take one of the UK biotech’s two pre­clin­i­cal pro­grams in­to a Phase I on­col­o­gy tri­al, with one op­tion be­ing a dual in­hibitor of hy­pox­ia-in­ducible fac­tor iso­topes, and the oth­er an AICAR trans­formy­lase/in­o­sine monophos­phate cy­clo­hy­dro­lase (AT­IC) dimer­iza­tion in­hibitor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.